Overexpression of Galectin-3 and its clinical significance in ovarian carcinoma

International Journal of Clinical Oncology

Volumn 16, Issue 4, 2011, Pages 352-358

  Kim, Min Kyu ^a   Sung, Chang Ohk ^a   Do, In Gu ^b   Jeon, Hye Kyung ^a   Song, Tae Jong ^a   Park, Hwang Shin ^a   Lee, Yoo Young ^a   Kim, Byoung Gie ^a   Lee, Jeong Won ^a   Bae, Duk Soo ^a  

^a Sungkyunkwan University   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Chemosensitivity; Galectin 3; Molecular target; Ovarian carcinoma; siRNA

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; GALECTIN 3; PACLITAXEL; SMALL INTERFERING RNA; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; DRUG SENSITIVITY; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; UPREGULATION;

CARCINOMA; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; GALECTIN 3; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; RNA, SMALL INTERFERING;

EID: 80052761841     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0190-x     Document Type: Article

References (35)

1. A Jemal R Siegel E Ward, et al. 2006 Cancer statistics, 2006 CA Cancer J Clin 56 106 130 16514137 10.3322/canjclin.56.2.106
2. K Kim SY Ryu 2009 Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer J Gynecol Oncol 20 198 19809557 10.3802/jgo.2009.20.3.198
3. S Banerjee M Gore 2009 The future of targeted therapies in ovarian cancer Oncologist 14 706 716 19592450 10.1634/theoncologist.2009-0013 1:CAS:528:DC%2BD1MXhtVOmtrnJ
4. SH Barondes DN Cooper MA Gitt, et al. 1994 Galectins. Structure and function of a large family of animal lectins J Biol Chem 269 20807 20810 8063692 1:CAS:528:DyaK2cXlsFWgurc%3D
5. J Hirabayashi K Kasai 1993 The family of metazoan metal-independent beta-galactoside-binding lectins: structure, function and molecular evolution Glycobiology 3 297 304 8400545 10.1093/glycob/3.4.297 1:CAS:528: DyaK2cXpvFGntw%3D%3D (Pubitemid 23281277)
6. MT Elola C Wolfenstein-Todel MF Troncoso, et al. 2007 Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival Cell Mol Life Sci 64 1679 1700 17497244 10.1007/s00018-007-7044-8 1:CAS:528:DC%2BD2sXos1Crsr0%3D (Pubitemid 47036942)
7. M Le Mercier S Fortin V Mathieu, et al. 2010 Galectins and gliomas Brain Pathol 20 17 27 19371355 10.1111/j.1750-3639.2009.00270.x 1:CAS:528: DC%2BC3cXpvFOnug%3D%3D
8. RY Yang GA Rabinovich FT Liu 2008 Galectins: structure, function and therapeutic potential Expert Rev Mol Med 10 e17 18549522 10.1017/ S1462399408000719 (Pubitemid 351850788)
9. PJ Davidson SY Li AG Lohse, et al. 2006 Transport of galectin-3 between the nucleus and cytoplasm. I. Conditions and signals for nuclear import Glycobiology 16 602 611 16473835 10.1093/glycob/cwj088 1:CAS:528: DC%2BD28XmsVejsrg%3D (Pubitemid 43985501)
10. J Ochieng V Furtak P Lukyanov 2004 Extracellular functions of galectin-3 Glycoconj J 19 527 535 14758076 10.1023/B:GLYC.0000014082.99675.2f (Pubitemid 38316526)
11. P Matarrese O Fusco N Tinari, et al. 2000 Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties Int J Cancer 85 545 554 10699929 10.1002/(SICI)1097-0215(20000215)85:4<545::AID-IJC17>3.0. CO;2-N 1:CAS:528:DC%2BD3cXht1amt74%3D (Pubitemid 30075135)
12. RY Yang DK Hsu FT Liu 1996 Expression of galectin-3 modulates T-cell growth and apoptosis Proc Natl Acad Sci USA 93 6737 6742 8692888 10.1073/pnas.93.13.6737 1:CAS:528:DyaK28XjvFeisbk%3D (Pubitemid 26230379)
13. S Akahani P Nangia-Makker H Inohara, et al. 1997 Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family Cancer Res 57 5272 5276 9393748 1:CAS:528:DyaK2sXnslGru7w%3D (Pubitemid 27516362)
14. RS Bresalier N Mazurek LR Sternberg, et al. 1998 Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3 Gastroenterology 115 287 296 9679034 10.1016/S0016-5085(98) 70195-7 1:CAS:528:DyaK1cXltl2nsrw%3D (Pubitemid 28363421)
15. F van den Brule S Califice V Castronovo 2004 Expression of galectins in cancer: a critical review Glycoconj J 19 537 542 14758077 10.1023/B:GLYC. 0000014083.48508.6a
16. FA van den Brule A Berchuck RC Bast, et al. 1994 Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas Eur J Cancer 30A 1096 1099 7654437 10.1016/0959-8049(94) 90464-2 (Pubitemid 24277834)
17. H Brustmann 2008 Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome Int J Gynecol Pathol 27 380 389 18580315 10.1097/PGP. 0b013e31815d060d
18. T Oishi H Itamochi J Kigawa, et al. 2007 Galectin-3 may contribute to cisplatin resistance in clear cell carcinoma of the ovary Int J Gynecol Cancer 17 1040 1046 17433067 10.1111/j.1525-1438.2007.00916.x 1:STN:280: DC%2BD2srlslCmtg%3D%3D (Pubitemid 47414828)
19. S Saussez C Decaestecker V Mahillon, et al. 2008 Galectin-3 upregulation during tumor progression in head and neck cancer Laryngoscope 118 1583 1590 18677282 10.1097/MLG.0b013e31817b0718 1:CAS:528:DC%2BD1cXhtVGnsL3L
20. JW Lee SJ Lee J Seo, et al. 2005 Increased expressions of claudin-1 and claudin-7 during the progression of cervical neoplasia Gynecol Oncol 97 53 59 15790437 10.1016/j.ygyno.2004.11.058 1:CAS:528:DC%2BD2MXis1GrsLo%3D (Pubitemid 40403674)
21. T Shimonishi K Miyazaki N Kono, et al. 2001 Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma Hum Pathol 32 302 310 11274640 10.1053/hupa.2001.22767 1:CAS:528:DC%2BD3MXjtVSgsLc%3D (Pubitemid 32246805)
22. S Nakahara A Raz 2008 Biological modulation by lectins and their ligands in tumor progression and metastasis Anticancer Agents Med Chem 8 22 36 18220503 10.2174/187152008783330833 1:CAS:528:DC%2BD1cXktVejtA%3D%3D (Pubitemid 351445058)
23. P Nangia-Makker V Hogan Y Honjo, et al. 2002 Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin J Natl Cancer Inst 94 1854 1862 12488479 1:CAS:528:DC%2BD3sXlsFyjuw%3D%3D (Pubitemid 36104630)
24. RS Bresalier PS Yan JC Byrd, et al. 1997 Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system Cancer (Phila) 80 776 787 10.1002/(SICI)1097-0142(19970815)80:4<776::AID-CNCR17>3.0.CO;2-Q 1:STN:280:DyaK2svgslKisQ%3D%3D (Pubitemid 27339834)
25. HL Schoeppner A Raz SB Ho, et al. 1995 Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon Cancer (Phila) 75 2818 2826 10.1002/1097-0142(19950615)75:12<2818::AID- CNCR2820751206>3.0.CO;2-# 1:STN:280:DyaK2M3pt1amsQ%3D%3D
26. J Miyazaki R Hokari S Kato, et al. 2002 Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes Oncol Rep 9 1307 1312 12375039 1:CAS:528:DC%2BD38XosFSrtLY%3D
27. PJ Davidson MJ Davis RJ Patterson, et al. 2002 Shuttling of galectin-3 between the nucleus and cytoplasm Glycobiology 12 329 337 12070075 10.1093/glycob/12.5.329 1:CAS:528:DC%2BD38XltlCqtr8%3D (Pubitemid 34812051)
28. Y Takenaka T Fukumori A Raz 2004 Galectin-3 and metastasis Glycoconj J 19 543 549 14758078 10.1023/B:GLYC.0000014084.01324.15 (Pubitemid 38316528)
29. K Balasubramanian R Vasudevamurthy SU Venkateshaiah, et al. 2009 Galectin-3 in urine of cancer patients: stage and tissue specificity J Cancer Res Clin Oncol 135 355 363 18836743 10.1007/s00432-008-0481-4 1:CAS:528:DC%2BD1MXht1Ogu70%3D
30. CI Lin EE Whang MA Abramson, et al. 2009 Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells Biochem Biophys Res Commun 379 626 631 19124005 10.1016/j.bbrc.2008.12.153 1:CAS:528:DC%2BD1MXotl2msA%3D%3D
31. BW Guess MC Scholz SB Strum, et al. 2003 Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study Prostate Cancer Prostatic Dis 6 301 304 14663471 10.1038/sj.pcan.4500679 1:CAS:528:DC%2BD3sXps1Siurc%3D (Pubitemid 38088192)
32. Y Takei K Kadomatsu Y Yuzawa, et al. 2004 A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics Cancer Res 64 3365 3370 15150085 10.1158/0008-5472.CAN-03-2682 1:CAS:528: DC%2BD2cXktVWhsrc%3D (Pubitemid 38657905)
33. SR Hingorani MA Jacobetz GP Robertson, et al. 2003 Suppression of BRAF (V599E) in human melanoma abrogates transformation Cancer Res 63 5198 5202 14500344 1:CAS:528:DC%2BD3sXntlekt7k%3D (Pubitemid 37139827)
34. TR Brummelkamp R Bernards R Agami 2002 Stable suppression of tumorigenicity by virus-mediated RNA interference Cancer Cell 2 243 247 12242156 10.1016/S1535-6108(02)00122-8 1:CAS:528:DC%2BD38Xnt1yhur8%3D (Pubitemid 41043979)
35. VV Glinsky G Kiriakova OV Glinskii, et al. 2009 Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo Neoplasia 11 901 909 19724684 1:CAS:528:DC%2BD1MXhtVKht7jP